140 likes | 144 Views
What Does the Future H old for Pharmacy? Being Part of the Solution Health Innovations Meeting Texas Medical Center September 2016. Linda Garrelts MacLean Clinical Professor and Vice Dean Spokane, WA lmaclean@wsu.edu 509-995-4926.
E N D
What Does the Future Hold for Pharmacy?Being Part of the SolutionHealth Innovations MeetingTexas Medical CenterSeptember 2016
Linda Garrelts MacLeanClinical Professor and ViceDeanSpokane, WA lmaclean@wsu.edu509-995-4926
What Does the Future Hold for Pharmacy: Implications for Colleges and Schools of Pharmacy
What are the top 10 emerging healthcare trends? Who does the trend affect? What are implications for patients and providers, including pharmacists? What are the implications for pharmacy education?
Drivers and Forces for Pharmacy Practice Transformation Barriers to implementing innovative pharmacy services? Strategies to overcome challenges?
Drivers and Forces for Pharmacy Practice Transformation The Affordable Care Act influence on transformation? Role of collaborative drug therapy agreements on transformation?
National Perspectives and Practice Advancement • National Alliance of State Pharmacy Associations • NASPA’s Pharmacist Collaborative Practice Agreements: Key Elements for Legislative and Regulatory Authority (http://naspa.us/wp-content/uploads/2015/07/CPA-Workgroup-Report-FINAL.pdf ) • Oregon • California • Washingon
National Perspectives and Practice Advancement American Pharmacists Association • www.pharmacistsprovidecare.com • http://avalerehealth.net/
Embracing “Future Practice” Now Increasing Access to Quality Patient Care in Community Pharmacies for Minor Illnesses in Washington State
Community Pharmacists Caring for Patients with Minor Ailments and Common Conditions Objective: As states implement the Triple Aim and seek to ensure access to quality care, innovative delivery models are being evaluated on the premise that improved access to care for patients in sites such as community pharmacies will result in more rapid assessment and initiation of therapy, improving patient health outcomes. Now: A3-phase analysis is being undertaken.
Minor Ailments and Common Conditions Research Care being provided in the community pharmacies. Collaborative drug therapy agreements being used. Pharmacies participating. Encounters and documentation.
Minor Ailments and Common Conditions Research • Phase One • feasibility and sustainability • Phase Two • cost • Phase Three • quality
Questions? Used with permission from WSPA